Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability.

Abstract

Oral fampridine prolonged release (PR) [Fampyra®] is a lipid-soluble selective potassium channel blocker that is approved in the EU for the improvement of walking in adult multiple sclerosis (MS) patients with walking disability (expanded disability status scale score of 4-7). In clinical trials (MS-F203 and MS-F204) using an objective measure of walking improvement [the timed 25-foot walk (T25FW)], more than one-third of patients receiving fampridinePR achieved a consistent on-treatment improvement in walking speed (i.e. became TW responders) over 9-14weeks of treatment. FampridinePR recipients who fulfilled the definition of TW responder had mean improvements of ≈25% from baseline in T25FW walking speed. In a clinical trial (ENHANCE) that used a patient-rated measure of walking improvement [12-item MS walking scale (MSWS-12)], a significantly greater proportion of fampridinePR recipients than placebo recipients achieved a ≥8-point improvement on the MSWS-12 with 24weeks of treatment. Where reported, adverse events were mostly mild or moderate in severity, and generally consistent with the underlying disease or mechanism of action of fampridinePR. FampridinePR is a useful treatment option to consider in adult MS patients with walking disability.